Circassia Pharmaceuticals (NIOX) Stock Statistics & Valuation Metrics

Circassia Pharmaceuticals has a market cap or net worth of £236.63M. The enterprise value is 217.73M .

Circassia Pharmaceuticals has 418,074,460 shares outstanding. The number of shares has decreased by -2.65% in one year.

Circassia Pharmaceuticals’s return on equity (ROE) is 0.09 and return on invested capital (ROIC) is 9.75%.

The current PE Ratio of Circassia Pharmaceuticals is 39.3. Circassia Pharmaceuticals’s PEG ratio is 0.43.

In the last 12 months, Circassia Pharmaceuticals had revenue of 48.70M and earned 7.00M in profits. Earnings per share was 0.02.

In the last 12 months, operating cash flow was 15.80M and capital expenditures -200.00K, giving a free cash flow of 15.60M billion.

Circassia Pharmaceuticals pays an annual dividend of 1.25 p, resulting in a dividend yield of 3.4%

Circassia Pharmaceuticals upcoming earnings date is Sep 10, 2026, Before Open (Confirmed).

Circassia Pharmaceuticals as a current ratio of 3.81, with Debt / Equity ratio of 1.36%

In the past 12 months, Circassia Pharmaceuticals has paid 4.20M in taxes.

Circassia Pharmaceuticals EV to EBITDA ratio is 23.94, with an EV/FCF ratio of 16.42.

Circassia Pharmaceuticals has £19.90M in cash and marketable securities with £1.00M in debt, giving a net cash position of £18.90M billion.

Gross margin is 60.78%, with operating margin of 21.97%, and net profit margin of 14.37%.

The average price target for Circassia Pharmaceuticals is £86.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy